Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
| Autor: | Hutson, Thomas E, Lesovoy, Vladimir, Al-Shukri, Salman, Stus, Viktor P, Lipatov, Oleg N, Bair, Angel H, Rosbrook, Brad, Chen, Connie, Kim, Sinil, Vogelzang, Nicholas J |
|---|---|
| Zdroj: | In Lancet Oncology December 2013 14(13):1287-1294 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|